Logo image of AMAG

Amag Pharmaceuticals (AMAG) Stock Fundamental Analysis

USA - NASDAQ:AMAG -

13.75
+0.02 (+0.15%)
Last: 11/13/2020, 8:00:46 PM
13.76
+0.01 (+0.07%)
After Hours: 11/13/2020, 8:00:46 PM
No Fundamental Analysis report for AMAG not available.

Amag Pharmaceuticals

NASDAQ:AMAG (11/13/2020, 8:00:46 PM)

After market: 13.76 +0.01 (+0.07%)

13.75

+0.02 (+0.15%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners15.72%
Ins Owner Change0%
Market Cap477.47M
Revenue(TTM)304.57M
Net Income(TTM)-227619000
Analysts60
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 76.39
P/S 1.57
P/FCF N/A
P/OCF N/A
P/B 1.86
P/tB N/A
EV/EBITDA -1.99
EPS(TTM)-2.3
EYN/A
EPS(NY)0.18
Fwd EY1.31%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.77
BVpS7.37
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -71.77%
PM (TTM) -74.73%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.75
Quick Ratio 1.61
Altman-Z -1.93
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.53%
EPS Next Y84.01%
EPS Next 2Y100.19%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.52%
Revenue growth 3YN/A
Revenue growth 5Y-6.15%
Sales Q2Q%10.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Amag Pharmaceuticals / AMAG FAQ

What is the fundamental rating for AMAG stock?

ChartMill assigns a fundamental rating of 3 / 10 to AMAG.


What is the valuation status for AMAG stock?

ChartMill assigns a valuation rating of 4 / 10 to Amag Pharmaceuticals (AMAG). This can be considered as Fairly Valued.


Can you provide the profitability details for Amag Pharmaceuticals?

Amag Pharmaceuticals (AMAG) has a profitability rating of 3 / 10.


What is the financial health of Amag Pharmaceuticals (AMAG) stock?

The financial health rating of Amag Pharmaceuticals (AMAG) is 1 / 10.


What is the expected EPS growth for Amag Pharmaceuticals (AMAG) stock?

The Earnings per Share (EPS) of Amag Pharmaceuticals (AMAG) is expected to grow by 84.01% in the next year.